Template:KDRG: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 13: Line 13:
#[[Deucravacitinib]]
#[[Deucravacitinib]]
#[[Ublituximab-xiiy]]
#[[Ublituximab-xiiy]]
#[[futibatinib]]
#[[LYTGOBI- futibatinib]]
#[[Tapinarof]]
#[[Tapinarof]]
#[[Spevigo- spesolimab-sbz]]
#[[Spevigo- spesolimab-sbz]]
Line 26: Line 26:
#[[Sparsentan]]
#[[Sparsentan]]
#[[BRENZAVVY- bexagliflozin]]
#[[BRENZAVVY- bexagliflozin]]
#[[Chronic obstructive pulmonary disease history and symptoms]]
#[[COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)]]
#[[COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)]]
#[[Nirsevimab]]
#[[Nirsevimab]]
Line 32: Line 31:
#[[EXXUA]]
#[[EXXUA]]
#[[Somatrogon-ghla]]
#[[Somatrogon-ghla]]
#[[Chronic renal failure overview]]
#[[Aprocitentan]]
#[[Aprocitentan]]
#[[WINREVAIR]]
#[[WINREVAIR]]
#[[Xolremdi]]
#[[Xolremdi]]
#[[Rytelo]]
#[[Chronic obstructive pulmonary disease history and symptoms]] New Guidelines 2024
#[[Chronic renal failure overview]] New Guidelines 2024
#[[Clinical assessment of lower extremity peripheral arterial disease]] New Guidelines 2024

Latest revision as of 18:17, 20 August 2024